Factor V leiden (FVL) mutations and thromboembolic events (TE) in women with breast cancer on adjuvant tamoxifen.

被引：0
|
作者：
Garber, JE
Halabi, S
Kaplan, E
Edge, S
Dressler, L
Paskett, E
Berliner, N
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Duke Univ, Durham, NC 27706 USA
[3] Roswell Pk Canc Inst, Buffalo, NY 14263 USA
[4] Univ N Carolina, Chapel Hill, NC USA
[5] Ohio State Univ, Columbus, OH 43210 USA
[6] Yale Univ, Sch Med, New Haven, CT 06520 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：6S / 6S
页数：1
相关论文
共 50 条
  • [21] Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer
    Hadji, P.
    Ziller, V
    Holzhauer, W.
    Ziller, M.
    Kalder, M.
    Wagner, U.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S146 - S146
  • [22] Cost-effectiveness of five years of extended adjuvant letrozole in postmenopausal women with early breast cancer who have completed five years of adjuvant tamoxifen.
    Delea, TE
    Karnon, J
    Smith, RE
    Brandman, J
    Sung, JC
    Goss, PPE
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S58 - S58
  • [23] Compliance with tamoxifen and arimidex in the adjuvant treatment of women with breast cancer
    Ziller, V.
    Holzhauer, W.
    Ziller, M.
    Wagner, U.
    Hadji, P.
    BREAST, 2007, 16 : S44 - S45
  • [24] Adherence to Adjuvant Tamoxifen in Mexican Young Women with Breast Cancer
    Martinez-Cannon, Bertha Alejandra
    Castro-Sanchez, Andrea
    Barragan-Carrillo, Regina
    Pacheco, Sylvia de la Rosa
    Platas, Alejandra
    Fonseca, Alan
    Vega, Yoatzin
    Bojorquez-Velazquez, Karen
    Bargallo-Rocha, Juan Enrique
    Mohar, Alejandro
    Villarreal-Garza, Cynthia
    PATIENT PREFERENCE AND ADHERENCE, 2021, 15 : 1039 - 1049
  • [25] Results from the UK NCRI Adjuvant Breast Cancer (ABC) International trial: Polychemotherapy and ovarian ablation in women with early breast cancer prescribed 5 years tamoxifen.
    Brunt, AM
    Bliss, JM
    Johnson, L
    Lawrence, D
    Yarnold, J
    BRITISH JOURNAL OF CANCER, 2004, 91 : S1 - S1
  • [26] Operabile breast cancer in postmenopausal women on adjuvant antiestrogen tamoxifen
    Veselinovic, S
    Filipovic, S
    Projevic, M
    Stojanovic, D
    Buric, M
    BALKAN CONGRESS OF ONCOLOGY, 1996, : 447 - 450
  • [27] Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer
    Partridge, AH
    Wang, PS
    Winer, EP
    Avorn, J
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (04) : 602 - 606
  • [28] Factor V leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - results from a prospective, single center, case control study
    Kovac, M.
    Kovac, Z.
    Tomasevic, Z.
    Vucicevic, S.
    Djordjevic, V
    Pruner, I
    Radojkovic, D.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 810 - 810
  • [29] Factor V Leiden mutation and high FVIII are associated with an increased risk of VTE in women with breast cancer during adjuvant tamoxifen - Results from a prospective, single center, case control study
    Kovac, Mirjana
    Kovac, Zeljko
    Tomasevic, Zorica
    Vucicevic, Slavko
    Djordjevic, Valentina
    Pruner, Iva
    Radojkovic, Dragica
    EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2015, 26 (01) : 63 - 67
  • [30] VARIANT ALLELES IN FACTOR V LEIDEN (FVL), PROTHROMBIN, PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1), METHYLENETETRAHYDROFOLATE REDUCTASE (MTHFR) AND RISK OF THROMBOEMBOLIC EVENTS (TEE) IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS
    Nichetti, Federico
    Falvella, Felicia Stefania
    Cheli, Stefania
    Colombo, Alessia
    Clementi, Emilio
    Cremolini, Chiara
    Antoniotti, Carlotta
    Loupakis, Fotios
    Marmorino, Federica
    Miceli, Rosalba
    Infante, Gabriele
    Martinetti, Antonia
    Di Bartolomeo, Maria
    Sottotetti, Elisa
    Berenato, Rosa
    Caporale, Marta
    Niger, Monica
    De Braud, Filippo
    Pietrantonio, Filippo
    ANTICANCER RESEARCH, 2016, 36 (01) : 231 - 232
12345